MedTrace Logo

Study to Investigate the Safety, Tolerability, Pharmacokinetics of PF-06305591 in Healthy Male and Female Subjects

NCT01747941 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2013-05-23

No results posted yet for this study

Summary

The study is designed to test safety tolerability and PK of single oral ascending doses of PF-06305591,

Conditions

  • Healthy

Interventions

DRUG

PF-06305591

single dose, solution

DRUG

Placebo

matching placebo

DRUG

PF-06305591

single dose, solution

DRUG

Placebo

matching placebo

DRUG

PF-06305591

single dose, solution

DRUG

Placebo

matching placebo

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01747941 on ClinicalTrials.gov